AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9032515 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox (50% nitrous oxide and 50% oxygen)
Number of subjects: 5
Study 9032515 — intervention group
Group type: COMPARATOR
Intervention: Gas chromatography method for TL,CO determination
Number of subjects: 5
Study 7684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 to 1.0 microgram per day orally) plus salmon calcitonin (400 IU per day intranasally)
Number of subjects: 103
Study 7684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 to 1.0 microgram per day orally) plus placebo nasal spray
Number of subjects: 103
Study 7684512 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1000 mg per day orally)
Number of subjects: 103
Study 7684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin plus calcitriol
Number of subjects: 103
Study 7684512 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 103
Study 7684512 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 103
Study 2963380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of carbazochrome sodium sulfonate (AC-17)
Number of subjects: 77
Study 2963380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 30511966 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (Riancorp LTU-904)
Number of subjects: 42
Study 30511966 — intervention group
Group type: COMPARATOR
Intervention: Inactive low-level laser therapy (placebo)
Number of subjects: 42
Study 25878160 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsh pharmacokinetic model
Number of subjects: 23
Study 25878160 — intervention group
Group type: EXPERIMENTAL
Intervention: PGIMER pharmacokinetic model
Number of subjects: 23
Study 24959347 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppressive protocol based on low-dose tacrolimus and mycophenolate mofetil (MMF) with antithymocyte globulin (ATG) induction
Number of subjects: 0
Study 24959347 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppressive protocol based on low-dose tacrolimus, MMF, and steroids with interleukin-2 receptor (IL2-R) induction
Number of subjects: 0
Study 24959347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study arms
Number of subjects: 0
Study 22430565 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI after surgical debridement and initiation of antibiotic therapy
Number of subjects: 12
Study 20593535 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1 (n = 47)
Number of subjects: 1135
Study 20593535 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m2 on days 1 and 8 plus paclitaxel 200 mg/m2 on day 1 (n = 42)
Number of subjects: 1135
Study 20593535 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel 225 mg/m2 on day 1 plus carboplatin area under the curve 6.0 on day 1 (n = 49)
Number of subjects: 1135
Study 20593535 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy doublet regimens (overall for white and African American patients)
Number of subjects: 1135
Study 18713910 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suctioning during pressure‐controlled ventilation
Number of subjects: 20
Study 18713910 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suctioning during volume‐controlled ventilation
Number of subjects: 20
Study 18713910 — intervention group
Group type: EXPERIMENTAL
Intervention: Open suctioning
Number of subjects: 20
Study 15652392 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg)
Number of subjects: 12
Study 15652392 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 12
Study 15652392 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 12
Study 12972792 — intervention group
Group type: EXPERIMENTAL
Intervention: Papanicolaou test
Number of subjects: 1008
Study 12972792 — intervention group
Group type: COMPARATOR
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 1008
Study 12862135 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM+BCG
Number of subjects: 80
Study 12862135 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 80
Study 8831305 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin treatment
Number of subjects: 16
Study 8831305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 16
Study 8831305 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF stimulated A549 cell culture supernatant
Number of subjects: 16
Study 8831305 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin and TLCK
Number of subjects: 16
Study 8398225 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite mammography program (print media, on-site workshops, and incentive drawings)
Number of subjects: 0
Study 8398225 — intervention group
Group type: COMPARATOR
Intervention: Control site (comparison site)
Number of subjects: 0
Study 3100312 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 7.5 mg kg‐1 body weight
Number of subjects: 20
Study 3100312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29596311 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise + isoflavone supplementation (ISO)
Number of subjects: 32
Study 29596311 — intervention group
Group type: COMPARATOR
Intervention: exercise + placebo (PLA)
Number of subjects: 32
Study 28077538 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 44
Study 28077538 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (Control)
Number of subjects: 44
Study 24958603 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril + candesartan
Number of subjects: 0
Study 24958603 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril + hydrochlorothiazide (HCT)
Number of subjects: 0
Study 24958603 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 0
Study 22499373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (B)
Number of subjects: 26
Study 22499373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (C)
Number of subjects: 26
Study 22499373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 26
Study 21160258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for older women with high-risk breast cancer features
Number of subjects: 0
Study 21160258 — intervention group
Group type: COMPARATOR
Intervention: Surgery, endocrine therapy, and radiotherapy
Number of subjects: 0
Study 18549460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus therapy
Number of subjects: 27
Study 15988077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate
Number of subjects: 110
Study 15988077 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (diuretics, ACE inhibitors, beta-blockers, digoxin)
Number of subjects: 110
Study 12717125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 15 microg/kg followed by mivacurium 0.1 mg/kg
Number of subjects: 20
Study 12717125 — intervention group
Group type: COMPARATOR
Intervention: Saline followed by mivacurium 0.13 mg/kg
Number of subjects: 20
Study 12717125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium-mivacurium group
Number of subjects: 20
Study 12717125 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium group
Number of subjects: 20
Study 10547085 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 0
Study 10547085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8669518 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple advice
Number of subjects: 1559
Study 8669518 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 1559
Study 8669518 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1559
Study 2058827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl group (n = 10): bolus injections of about 0.2 mg/h fentanyl and 2.5 mg/h midazolam
Number of subjects: 20
Study 2058827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine group (n = 10): infusion of about 50 mg/h ketamine and 2.5 mg/h midazolam
Number of subjects: 20
Study 6327346 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline sulphate orally
Number of subjects: 8
Study 6327346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline sulphate subcutaneously
Number of subjects: 8
Study 6327346 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 8
Study 31334793 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 448
Study 31334793 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 448
Study 31334793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 29584549 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-Paclitaxel-Trastuzumab (experimental arm)
Number of subjects: 61
Study 29584549 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-Paclitaxel (control arm)
Number of subjects: 61
Study 27230022 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitii (multi-modal web-based rehabilitation) for 20 weeks, 30 minutes per day, 6 days per week
Number of subjects: 58
Study 27230022 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait list control)
Number of subjects: 58
Study 24606670 — intervention group
Group type: EXPERIMENTAL
Intervention: CERAMENT™ BONE VOID FILLER (CBVF)
Number of subjects: 136
Study 24606670 — intervention group
Group type: COMPARATOR
Intervention: Autologous iliac crest bone graft
Number of subjects: 136
Study 22577718 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug and Caltrate D (600 mg/day)
Number of subjects: 27
Study 22577718 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drug, Caltrate D (600 mg/day), and Alendronate (70 mg weekly)
Number of subjects: 27
Study 22577718 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 healthy voluntary adults)
Number of subjects: 27
Study 20008417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 383
Study 20008417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Glycerol
Number of subjects: 383
Study 20008417 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 383
Study 20008417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 17272253 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming and humidification of inspired gases (Group HUM)
Number of subjects: 200
Study 17272253 — intervention group
Group type: COMPARATOR
Intervention: Ventilation without airway warming and exogenous humidification (Group C-control)
Number of subjects: 200
Study 16274306 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 30
Study 16274306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (propylene glycol alginate [PGA])
Number of subjects: 30
Study 12145006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat cereal
Number of subjects: 36
Study 12145006 — intervention group
Group type: COMPARATOR
Intervention: Wheat cereal
Number of subjects: 36
Study 10442322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound (OHC) 3.32 g/d
Number of subjects: 60
Study 10442322 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 2.5 g/d
Number of subjects: 60
Study 10442322 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 60
Study 7842191 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring of peak expiratory flow rate (PEFR) with educational intervention
Number of subjects: 70
Study 7842191 — intervention group
Group type: COMPARATOR
Intervention: Control group using symptoms and spirometric data
Number of subjects: 70
Study 2359576 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home uterine activity monitoring and perinatal nursing support
Number of subjects: 67
Study 2359576 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study 364637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg daily
Number of subjects: 60
Study 364637 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 75 mg daily
Number of subjects: 60
Study 31358624 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraising academic and social adversity intervention
Number of subjects: 1304
Study 31358624 — intervention group
Group type: COMPARATOR
Intervention: Control condition activities
Number of subjects: 1304
Study 30053074 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (brisk walking), adherence 166.0±66.1 minutes/week
Number of subjects: 144
Study 30053074 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 144
Study 30053074 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (brisk walking)
Number of subjects: 144
Study 26346408 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM (therapeutic drug monitoring)
Number of subjects: 29
Study 26346408 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (clinician-driven)
Number of subjects: 29
Study 26346408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 22974254 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 40 µg, tid for 8 weeks
Number of subjects: 99
Study 22974254 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 99
Study 22974254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 21901911 — intervention group
Group type: EXPERIMENTAL
Intervention: New health benefit plan changes for obese employees
Number of subjects: 658
Study 21901911 — intervention group
Group type: EXPERIMENTAL
Intervention: New health benefit plan changes focused on obesity
Number of subjects: 658
Study 21901911 — intervention group
Group type: EXPERIMENTAL
Intervention: New health benefit plan changes focused on tobacco use
Number of subjects: 658
Study 18567066 — intervention group
Group type: EXPERIMENTAL
Intervention: Consider‐An‐Alternative debiasing procedure
Number of subjects: 0
Study 18567066 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17896582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-ketoglutaric acid calcium salt (6 g AKG and 1.68 Ca/day)
Number of subjects: 76
Study 17896582 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone (1.68 Ca/day)
Number of subjects: 76
Study 14719145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative group (lactulose)
Number of subjects: 105
Study 14719145 — intervention group
Group type: COMPARATOR
Intervention: Constipated group (codeine phosphate)
Number of subjects: 105
Study 14719145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 12439361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam; specific agonism of dopamine‐1 receptors; details on dosage and duration not available
Number of subjects: 0
Study 12439361 — intervention group
Group type: COMPARATOR
Intervention: Placebo; control group in randomized trial
Number of subjects: 0
Study 9625684 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg/d
Number of subjects: 156
Study 9625684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 7948230 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial solution (1.36% glucose and 1% peptides, 381 mOsm/kg)
Number of subjects: 20
Study 7948230 — intervention group
Group type: COMPARATOR
Intervention: Control solution (2.27% glucose, 404 mOsm/kg)
Number of subjects: 20
Study 3345279 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 1 in 200,000
Number of subjects: 80
Study 3345279 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 80
Study 3345279 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 80
Study 29169605 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study 29169605 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin-warfarin
Number of subjects: 2199
Study 28559862 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (EXP) - Treatment as Usual plus Cognitive Behavioral Therapy for psychosis, Family Intervention for psychosis, and Case Management.
Number of subjects: 260
Study 28559862 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - Personalized outpatient psychopharmacological treatment and non-specific supportive clinical management.
Number of subjects: 260
Study 28559862 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (EXP) - Family Intervention for psychosis.
Number of subjects: 260
Study 28559862 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - No specific family intervention.
Number of subjects: 260
Study 25540274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-IPV followed by HepB dose 1 month later (Group 1, n = 145)
Number of subjects: 280
Study 25540274 — intervention group
Group type: COMPARATOR
Intervention: Tdap-IPV and HepB administered simultaneously (Group 2, n = 135)
Number of subjects: 280
Study 25540274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 280
Study 23545612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (1mg/kg/day for 3 days, then increased by 1mg/kg/day every third day up to 6mg/kg/day)
Number of subjects: 40
Study 23545612 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (10mg/kg/day for 5 days, then increased by 10mg/kg/day every 5 days up to 60mg/kg/day)
Number of subjects: 40
Study 23545612 — intervention group
Group type: COMPARATOR
Intervention: Crossover to the other drug after initial treatment
Number of subjects: 40
Study 23545612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate or Levetiracetam
Number of subjects: 40
Study 21762177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered immediately after the Trier Social Stress Test (Alc0, n = 11)
Number of subjects: 25
Study 21762177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered 30 minutes after the Trier Social Stress Test (Alc30, n = 14)
Number of subjects: 25
Study 21762177 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 30 minutes after the Trier Social Stress Test (Alc0 group)
Number of subjects: 25
Study 21762177 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered immediately after the Trier Social Stress Test (Alc30 group)
Number of subjects: 25
Study 18850350 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Strengthening Programme (PRST), 10-week duration
Number of subjects: 13
Study 16601576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (alone or in combination with atenolol)
Number of subjects: 9
Study 16601576 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (alone or in combination with felodipine)
Number of subjects: 9
Study 16601576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/atenolol group
Number of subjects: 9
Study 16601576 — intervention group
Group type: COMPARATOR
Intervention: Candesartan/felodipine group
Number of subjects: 9
Study 14651725 — intervention group
Group type: EXPERIMENTAL
Intervention: KT3‐671 40 mg
Number of subjects: 0
Study 14651725 — intervention group
Group type: EXPERIMENTAL
Intervention: KT3‐671 80 mg
Number of subjects: 0
Study 14651725 — intervention group
Group type: EXPERIMENTAL
Intervention: KT3‐671 160 mg
Number of subjects: 0
Study 14651725 — intervention group
Group type: EXPERIMENTAL
Intervention: KT3‐671 (all doses)
Number of subjects: 0
Study 14651725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14635321 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 92
Study 14635321 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study 8733487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin administered eight hourly aiming for a peak concentration of 10 mg/l and trough below 2 mg/l (Group A)
Number of subjects: 29
Study 8733487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin administered as two equal 12 hourly doses (Group B)
Number of subjects: 29
Study 8733487 — intervention group
Group type: COMPARATOR
Intervention: Comparison of average peak tobramycin levels
Number of subjects: 29
Study 8733487 — intervention group
Group type: COMPARATOR
Intervention: Comparison of average trough tobramycin levels
Number of subjects: 29
Study 8733487 — intervention group
Group type: COMPARATOR
Intervention: Length of hospital stay, readmission rate, and mortality
Number of subjects: 29
Study 1444287 — intervention group
Group type: COMPARATOR
Intervention: Didanosine 375 mg alone
Number of subjects: 12
Study 1444287 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 375 mg with ranitidine 150 mg (ranitidine given 2 h prior)
Number of subjects: 12
Study 1444287 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg alone
Number of subjects: 12
Study 1444287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg with didanosine 375 mg
Number of subjects: 12
Study 3980378 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 6
Study 3980378 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 6
Study 31889999 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program designed to improve cardiovascular risk management through empowerment
Number of subjects: 0
Study 31889999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary feasibility study
Number of subjects: 0
Study 30068305 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 40
Study 30068305 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline solution)
Number of subjects: 40
Study 26840904 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program, twice per week for 12 weeks
Number of subjects: 159